Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
3 September 2024

ORYZON continues to strengthen its patent portfolio for vafidemstat with additional “Decision to grant” communications

25-26 September 2024

Sachs Annual Biotech in Europe Forum 2024

Mövenpick Hotel Basel

Basel

Switzerland

21-24 September 2024

European College of Neuropsychopharmacology (ECNP) congress 2024

Allianz MiCo convention center, Milan

MI

Italy

2-3 September 2024

German Fall Conference 2024

Le Meridien Hotel

Frankfurt

Germany

29 August 2024

ORYZON to provide corporate progress updates at several events in September

31 July 2024

ORYZON reports financial results and corporate update for half-year ending June 30, 2024

8 July 2024

ORYZON receives “Decision to grant” for two important patents for vafidemstat in Japan

28 June 2024

ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders

26 June 2024

ORYZON announces presentation of final data from PORTICO, vafidemstat’s global Phase IIb trial in Borderline Personality Disorder, at the 37th ECNP annual conference

14 June 2024

ORYZON presents preliminary data from ongoing Phase Ib FRIDA trial with iadademstat plus gilteritinib in relapsed/refractory FLT3-mut AML patients at EHA-2024

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Current page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel